biocon biologics

Claire Mazumdar, 37 years of age, currently heads Bicara Therapeutics as its founder and CEO. The firm, which was incubated by Biocon and later listed on NASDAQ, went public in 2024 and now has a market valuation of over $1.6 billion.

Why Claire Mazumdar? Because, according to her aunt and Biocon founder Kiran Mazumdar-Shaw, "I think she has proved to me that she can run a company."

D Y Patil International University hosted a two-day national conference on “AI & Model-Driven Strategies for Smart Biomanufacturing and Sustainable Food Production,” gathering experts from academia, industry, and research institutions. Keynote and technical sessions highlighted AI applications in pharmaceuticals, biologics, plant-based proteins, and waste-to-wealth strategies. Young researchers showcased papers and posters, while student activities encouraged engagement. The event emphasized intelligent automation, genomic strategies, and sustainable solutions, underscoring AI’s transformative role in biomanufacturing and future food sustainability.

biocon biologics, the biosimilar arm of Biocon, clocked its highest ever revenue of Rs 1,507 crore in the quarter ended December. Some of that was on account of the acquisition of Viatris’ biologics business, which was announced in February last year, and concluded in November.

biocon biologics, a subsidiary and flagship business of Bengaluru-based Biocon, has appointed Shreehas Tambe, as the managing director and CEO of the company. Tambe took over from Arun Chandavarkar, who continues to serve as a non-executive, non-independent director on the board.

biocon biologics, a subsidiary of Biocon, has completed the acquisition of the global biosimilars business of its partner Viatris.

Biocon has announced a bold step in the biopharmaceutical landscape by merging its biosimilars division, biocon biologics, into the parent organization for $5.5 billion. This ambitious strategy is designed to streamline operations and amplify its influence across global markets, especially in diabetes care, cancer treatment, and immune therapies.

Biocon has clocked a revenue of Rs 3,020 crore in the quarter ended December, an increase of 36% over the same quarter in the previous year. Of all the businesses Biocon has, biocon biologics registered a revenue of Rs 1,507 crore, up 54%.

Tata Capital Growth Fund has invested about $30 million for a 0.85% stake in biocon biologics, the biosimilar arm of Biocon, valuing the company at an equity valuation of $3.5 billion and enterprise valuation of $4 billion. The equity infusion will help the company through capital allocation, while it continues its investments in R&D and manufacturing to meet worldwide demand.

biocon biologics has been featured on the prestigious Asia IP Elite list for 2022 by lntellectual Asset Management (lAM) for its intellectual property (IP) management and IP value creation in the Asia-Pacific region.

biocon biologics signs settlement and license agreement with Janssen Biotech and Johnson & Johnson to commercialize Bmab 1200, a biosimilar to Stelara, in the US once approved by the USFDA. The therapy is expected to launch in February 2025.

biocon biologics, the biosimilar arm of Biocon, has got a $150 million funding from Wall Street behemoth Goldman Sachs, valuing the company at about $4 billion. Goldman will be issued optionally convertible debentures. The funding will help the unit make investments in R&D, manufacturing as well as expand its reach in the global market.

biocon biologics has reached a settlement with Regeneron, allowing the launch of Yesafili, its biosimilar eye drug, in the US by the second half of 2026. Approved by the USFDA as an interchangeable biosimilar to Eylea, Yesafili targets vision-related conditions. A similar settlement in Canada paves the way for a launch there by July 1, 2025.

biocon biologics, a subsidiary of Biocon has signed a distribution agreement with Sandoz, granting the company exclusive rights to promote, sell and distribute `Adalimumab BS for subcutaneous injection [FKB]’* in Japan. Based on this, Viatris has completed marketing and promotion of the product as of December 15, but will continue to provide transition support until Sandoz will gradually assume responsibilities for the product starting February 15, 2024, a company statement said.

biocon biologics, the biosimilar arm of Biocon, has got an investment of $75 (Rs 555 crore) million from Abu Dhabi’s sovereign wealth fund ADQ, as the unit continues to attract marquee investors globally before it goes public in the next two years.

Kiran Mazumdar-Shaw has made one of her boldest moves, acquiring a business that’s about the size of her own company for $3. 3 billion. biocon biologics, a subsidiary of MazumdarShaw’s Biocon, is acquiring the biosimilar assets of US-based Viatris (formerly Mylan). Viatris’s annual biosimilar revenue is about $1 billion, about the same as Biocon’s overall revenue.

Biocon’s revenue in the quarter ended September rose 23% to Rs 2,384 crore, compared to the same quarter last year. The biopharmaceutical company’s net profit was down 66% to Rs 47 crore.

biocon biologics and Viatris (formerly Mylan) have launched cancer drug bevacizumab under the brand name Abevmy in Canada. Abevmy was co-developed by the two companies. It is a biosimilar to Roche’s Avastin and has been approved by Health Canada across four oncology indications.